D89.810
BillableAcute graft-versus-host disease
Last updated: FY2026 ICD-10-CM (Oct 1, 2025 – Sep 30, 2026) | CMS-HCC V28 (100% phase-in, PY2026)
Is D89.810 an HCC code?
Yes. D89.810 maps to Graft-Versus-Host Disease and Stem Cell Transplant Complications under the CMS-HCC V28 risk adjustment model (and Disorders of Immunity under V24).
HCC Category Mapping
RAF weights shown are the community, non-dual, aged base weights from the CMS risk adjustment model file. Actual per-patient RAF contribution depends on member segment, interactions, and the model year used by the payer. V28 is the CMS-HCC model phased in over payment years 2024–2026; V24 remains in use during the transition and for historical data.
MEAT Criteria for D89.810
For D89.810 to count as a valid HCC diagnosis in a given encounter, the provider's documentation must show MEAT: Monitor, Evaluate, Assess, or Treat. A diagnosis from a prior year does not carry forward automatically — it has to be re-documented and supported each calendar year.
- MMonitor: signs, symptoms, disease progression, or lab trending documented in the note
- EEvaluate: test results, medication response, or physical findings reviewed by the provider
- AAssess: explicit mention in the assessment or plan with acknowledgment of status
- TTreat: medication, referral, procedure, therapy, or counseling tied to the diagnosis
Only one of M/E/A/T is required to support the code, but the documentation must be specific enough to show that the provider actually addressed D89.810 during that encounter — not just copy-forwarded from a problem list.
What This Code Means
D89.810 is the ICD-10-CM diagnosis code for acute graft-versus-host disease. A serious complication occurring shortly after a bone marrow or stem cell transplant where the donor's immune cells attack the recipient's body tissues. D89.810 sits in the ICD-10-CM chapter for diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism (d50-d89), within the section covering certain disorders involving the immune mechanism (d80-d89).
Under the CMS-HCC V28 risk adjustment model, D89.810 maps to Graft-Versus-Host Disease and Stem Cell Transplant Complications (HCC 454) with a community, non-dual, aged base RAF weight of 0.000. Under the older CMS-HCC V24 model, D89.810 maps to Disorders of Immunity (HCC 47) with a community, non-dual, aged base RAF weight of 0.472. V28 is the CMS-HCC risk adjustment model that reached 100% phase-in for payment year 2026, replacing V24 which was used during the PY2024–PY2025 transition.
Document the timeline (typically within 100 days of transplant) and affected organs. Because D89.810 maps to a payment HCC, the provider's documentation must satisfy MEAT criteria (Monitor, Evaluate, Assess, or Treat) for the encounter to count toward the patient's Medicare Advantage risk adjustment score. When documentation is ambiguous, coders should issue a provider query rather than assume the highest-specificity variant.
HCC Buddy maintains structured V28 and V24 mapping, RAF weights, and MEAT documentation criteria for D89.810 sourced directly from the CMS-HCC risk adjustment model files and the CMS ICD-10-CM code set.
Coding Tips
- •Document the timeline (typically within 100 days of transplant) and affected organs
- •Use with a code for the transplant procedure and specify affected body systems
Clinical Significance
Acute graft-versus-host disease is a potentially life-threatening immune complication occurring typically within the first 100 days after allogeneic hematopoietic stem cell transplantation, where donor immune cells attack the recipient's tissues. Primary target organs are skin (dermatitis), liver (elevated bilirubin), and gastrointestinal tract (diarrhea, abdominal pain). Severity grading (I-IV) guides treatment intensity, with Grade III-IV carrying significant mortality risk.
Documentation Requirements
- ✓Documentation must specify acute graft-versus-host disease with the organ systems involved (skin, liver, gastrointestinal), severity grading, and the temporal relationship to the transplant.
- ✓The type of transplant (allogeneic hematopoietic stem cell), conditioning regimen, and donor relationship should be recorded.
- ✓Current treatment including immunosuppressive therapy (corticosteroids, calcineurin inhibitors) and response to treatment must be documented.